Viberti (Eluxadoline) - Indication
Viberti (eluxadoline) is FDA-approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. 1
Mechanism of Action
Eluxadoline is a minimally absorbed mixed opioid receptor modulator that works as:
- μ-opioid receptor agonist (reduces pain and slows gut motility)
- κ-opioid receptor agonist (enhances analgesic effects)
- δ-opioid receptor antagonist (reduces constipation risk compared to pure opioid agonists)
This unique profile was specifically designed to improve both abdominal pain and diarrhea while minimizing constipation that occurs with traditional opioids 1.
Clinical Efficacy
The drug demonstrates moderate-quality evidence for:
- Composite symptom relief: 27-30% of patients achieve simultaneous improvement in both abdominal pain and stool consistency versus 16-17% with placebo 1
- Stool consistency improvement: Significant reduction in loose stools
- Urgency reduction: 50% reduction in urgency-free days
- Quality of life: Clinically meaningful improvements in IBS-specific quality of life measures 1
Dosing
- Standard dose: 100 mg twice daily with food 1
- Reduced dose: 75 mg twice daily for patients with:
- Intolerance to 100 mg dose
- Mild to moderate hepatic impairment
- Concurrent use of OATP1B1 inhibitors 1
Critical Contraindications
Eluxadoline is absolutely contraindicated in:
- Patients without a gallbladder (post-cholecystectomy)
- Patients consuming >3 alcoholic beverages per day
- History of pancreatitis
- History of sphincter of Oddi dysfunction
- Severe hepatic impairment 1
These contraindications exist due to serious pancreatitis risk—5 cases of pancreatitis and 8 cases of sphincter of Oddi spasm occurred in clinical trials, all associated with absent gallbladder or alcohol abuse 1.
Common Adverse Effects
- Constipation (8%)
- Nausea (7%)
- Abdominal pain (7%)
- Discontinuation rate: approximately 8% versus 4% with placebo 1
Clinical Positioning
The 2022 AGA guidelines provide a conditional recommendation (moderate certainty evidence) for eluxadoline as a treatment option in IBS-D 1. The 2021 British Society of Gastroenterology guidelines position it as a second-line therapy in secondary care, noting it is likely among the most efficacious options for IBS-D when used appropriately 2.
Key clinical caveat: Always verify gallbladder status and alcohol consumption before prescribing—this is non-negotiable given the pancreatitis risk profile.